Characteristics | amount | Percentage(%) |
---|---|---|
Age (years) | ||
Median | 56.1 | |
Range | 35–69 | |
Course of disease | ||
Average (months) | 6.6 | |
Range | 40 days-2 years | |
UICC staging | ||
T1 | 4 | 21.1 |
T2 | 7 | 36.8 |
T3 | 7 | 36.8 |
T4 | 1 | 5.3 |
Lymph node stations clinically involved | ||
Fixed inguinal lymph node | 17 | 89.5 |
Fixed inguinal lymph node + pelvic lymph node enlargement | 2 | 10.5 |
Broders’classifcation | ||
Well differentiated | 4 | 21.1 |
Moderately differentiated | 7 | 36.8 |
Poorly differentiated | 8 | 42.1 |
Clinical response to chemotherapy | ||
Progression | 2 | 10.5 |
Stable disease | 5 | 26.3 |
Partial or complete response | 12 | 63.2 |
Treatment after neoadjuvant chemotherapy | ||
ILND+PLND | 5 | 26.3 |
Penile partial resection + ILND + PLND | 6 | 31.6 |
Penectomy + ILND + PLND | 1 | 5.3 |
Radiotherapy | 7 | 36.8 |
Recurrence and metastasis after treatment | ||
pelvic lymph node metastasis only | 2 | 10.5 |
pelvic lymph node + bone metastasis | 2 | 10.5 |
pelvic lymph node + pulmonary metastasis | 3 | 15.8 |
pelvic lymph node + liver metastasis | 3 | 15.8 |
widespread lymph node metastases | 1 | 5.3 |